Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | aldesleukin | NCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | Phase 3 | 2021-09-30 | 2025-01-30 | +1218 days |
| 2026-11-20 | Gemcitabine, Sintilimab | NCT05979818Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer | Phase 1/2 | 2025-08-31 | 2028-10-31 | +1157 days |
| 2026-11-20 | NMS-03597812 | NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | 2029-09-15 | 2026-09-24 | −1087 days |
| 2026-11-20 | Capecitabine, Gemcitabine, Eribulin mesylate | NCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | Phase 3 | 2025-12 | 2027-12-31 | +760 days |
| 2026-11-20 | Dexamethasone, Ofatumumab, Rituximab, Blinatumomab, Methotrexate | NCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-20 | Methotrexate | NCT06252870Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | Phase 2 | 2027-10-18 | 2029-10-18 | +731 days |
| 2026-11-20 | Bortezomib, Abatacept | NCT05289167Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) | Phase 1/2 | 2026-08 | 2027-11 | +457 days |
| 2026-11-20 | Disitamab Vedotin | NCT06660511Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. | Phase 1 | 2025-09-01 | 2026-12-01 | +456 days |
| 2026-11-20 | Semaglutide (Ozempic) | NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide | Phase 2/3 | 2027-01 | 2027-12 | +334 days |
| 2026-11-20 | Pembrolizumab | NCT06249048Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Phase 1/2 | 2027-05 | 2026-06-17 | −318 days |
| 2026-11-20 | Esomeprazole | NCT06561542A Phase I Study of LX22001 for Injection in Healthy Subjects | Phase 1 | 2025-11-21 | 2025-01-23 | −302 days |
| 2026-11-20 | Atezolizumab | NCT05498896Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | Phase 2 | 2026-08-31 | 2027-05-31 | +273 days |
| 2026-11-20 | Elacestrant, Abemaciclib | NCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | 2026-12 | 2027-08 | +243 days |
| 2026-11-20 | Letrozole | NCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Phase 3 | 2027-07-01 | 2028-02-01 | +215 days |
| 2026-11-20 | Ferric derisomaltose | NCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy | Phase 3 | 2026-12-31 | 2026-05-31 | −214 days |
| 2026-11-20 | Blinatumomab | NCT03595917ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Phase 1 | 2026-11-01 | 2027-06-01 | +212 days |
| 2026-11-20 | Capivasertib, Osimertinib | NCT07486648Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib | Phase 1/2 | 2028-10-15 | 2029-05-15 | +212 days |
| 2026-11-20 | Selinexor | NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 2026-12 | 2026-06-02 | −182 days |
| 2026-11-20 | Sapanisertib | NCT06385496Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | Phase 2 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-20 | Sapanisertib | NCT06390865Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | Phase 2 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-20 | Axitinib intravitreal implant (OTX-TKI) | NCT05695417Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | Phase 1 | 2024-01 | 2024-05-28 | +148 days |
| 2026-11-20 | BI 3000202 | NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood | Phase 1 | 2027-02-21 | 2026-10-11 | −133 days |
| 2026-11-20 | ontunisertib | NCT07672574Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers | Phase 1 | 2026-09-26 | 2027-01-31 | +127 days |
| 2026-11-20 | Rifaximin SSD | NCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Phase 3 | 2025-09 | 2025-12-23 | +113 days |
| 2026-11-20 | Exemestane | NCT03125746A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | Phase 1 | 2021-10-28 | 2021-07-21 | −99 days |
| 2026-11-20 | Zoledronic acid | NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | 2027-01 | 2027-04 | +90 days |
| 2026-11-20 | Oxycodone (Xtampza ER) | NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing. | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-20 | Xanomeline/trospium chloride | NCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants | Phase 1 | 2026-12-03 | 2026-09-28 | −66 days |
| 2026-11-20 | Goserelin | NCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) | Phase 3 | 2035-10 | 2035-12 | +61 days |
| 2026-11-20 | SHR-1139 | NCT07078695A Trial of SHR-1139 in Healthy Volunteers | Phase 1 | 2026-09-30 | 2026-11-09 | +40 days |
| 2026-11-20 | Semaglutide (Wegovy) | NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | 2031-02 | 2031-03 | +28 days |
| 2026-11-20 | Pembrolizumab | NCT03161431SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | Phase 1 | 2026-08 | 2026-07-31 | −1 day |
| 2026-11-20 | AR1001 | NCT03625622Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease | Phase 2 | 2020-12-22 | 2020-12-21 | −1 day |
| 2026-11-19 | Nivolumab | NCT05795244Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | Phase 2 | 2029-12 | 2026-02-24 | −1376 days |
| 2026-11-19 | Anakinra | NCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children | Phase 3 | 2025-06-01 | 2027-10-01 | +852 days |
| 2026-11-19 | Silevertinib | NCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Phase 1/2 | 2025-11-03 | 2028-03 | +849 days |
| 2026-11-19 | Trastuzumab Deruxtecan, Afatinib | NCT06085755Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer | Phase 1/2 | 2025-12 | 2027-12-01 | +730 days |
| 2026-11-19 | Pregabalin | NCT04322305Pregabalin Trial for the Treatment of Alcohol Use Disorder | Phase 2 | 2025-06-30 | 2023-07-31 | −700 days |
| 2026-11-19 | CRMA-1001 | NCT07200193A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B | Phase 1/2 | 2032-12-31 | 2031-02 | −699 days |
| 2026-11-19 | Colesevelam | NCT06197763Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation. | Phase 1/2 | 2025-11-01 | 2027-07-30 | +636 days |
| 2026-11-19 | Fulvestrant | NCT05826964Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | Phase 2 | 2026-07-31 | 2027-11-30 | +487 days |
| 2026-11-19 | Niraparib, Bevacizumab | NCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Phase 2 | 2023-03-31 | 2024-07-11 | +468 days |
| 2026-11-19 | Almonertinib | NCT06463171Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | Phase 2 | 2026-06 | 2027-08-01 | +426 days |
| 2026-11-19 | tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), Bictegravir | NCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | Phase 2/3 | 2028-01 | 2026-11-03 | −424 days |
| 2026-11-19 | Dexamethasone, Docetaxel | NCT04947189Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | Phase 1/2 | 2026-07 | 2027-07-01 | +365 days |
| 2026-11-19 | Azacitidine, Venetoclax | NCT07163793Pilot Study of Reduced Venetoclax Exposure | Phase 2 | 2026-10 | 2027-10 | +365 days |
| 2026-11-19 | Ruxolitinib (Jakafi), Abatacept | NCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | Phase 2 | 2026-12-10 | 2027-12-10 | +365 days |
| 2026-11-19 | Tislelizumab | NCT07389187Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | 2026-12 | 2027-12 | +365 days |
| 2026-11-19 | Selpercatinib | NCT05668962Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | 2025-03-01 | 2026-01-13 | +318 days |
| 2026-11-19 | teduglutide (Gattex) | NCT07400783TED_ORG: Study on Short Bowel Syndrome | Phase na | 2026-03 | 2027-01 | +306 days |
| 2026-11-19 | Tamoxifen (Soltamox) | NCT05156892Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | Phase 1 | 2026-01-01 | 2026-11-01 | +304 days |
| 2026-11-19 | Cadonilimab | NCT05063916Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | Phase 2 | 2027-08-01 | 2026-11-11 | −263 days |
| 2026-11-19 | Methylprednisolone, abrocitinib, tofacitinib | NCT06119490Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis | Phase 1 | 2026-07 | 2025-10-14 | −260 days |
| 2026-11-19 | Sacituzumab Govitecan | NCT04559230Sacituzumab Govitecan in Recurrent Glioblastoma | Phase 2 | 2027-02 | 2027-08 | +181 days |
| 2026-11-19 | Povetacicept | NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Phase 2/3 | 2028-12-29 | 2029-06-27 | +180 days |
| 2026-11-19 | PF-08634404, Pembrolizumab | NCT06980272SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Phase 3 | 2026-07-30 | 2026-02-01 | −179 days |
| 2026-11-19 | Psilocybin (COMP360) | NCT07373535Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy | Phase 2 | 2028-07 | 2028-12 | +153 days |
| 2026-11-19 | Ticagrelor | NCT06691191Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors | Phase 4 | 2026-08-31 | 2026-12-31 | +122 days |
| 2026-11-19 | AND017 | NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | Phase 3 | 2026-10-30 | 2027-02-20 | +113 days |
| 2026-11-19 | Tremelimumab, Olaparib, Durvalumab | NCT03699449An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | Phase 2 | 2022-09 | 2022-05-17 | −107 days |
| 2026-11-19 | AND017 | NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | Phase 3 | 2026-12-01 | 2027-03-01 | +90 days |
| 2026-11-19 | Nivolumab | NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Phase 1 | 2027-01-31 | 2026-11-12 | −80 days |
| 2026-11-19 | tocilizumab | NCT05207670A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | Phase 2 | 2027-07-31 | 2027-10-01 | +62 days |
| 2026-11-19 | efsubaglutide alfa | NCT07114419The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE) | Phase 2 | 2026-06-01 | 2026-07-06 | +35 days |
| 2026-11-19 | Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, Carfilzomib | NCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Phase 3 | 2028-10-31 | 2028-11-30 | +30 days |
| 2026-11-19 | tilrekimig | NCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time | Phase 3 | 2034-05-12 | 2034-04-21 | −21 days |
| 2026-11-19 | Depemokimab, Mepolizumab | NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | 2026-09-29 | 2026-10-06 | +7 days |
| 2026-11-19 | stapokibart | NCT05728684Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease | Phase na | 2024-02-28 | 2024-02-26 | −2 days |
| 2026-11-18 | Sintilimab, Bevacizumab | NCT05363722Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC | Phase 1 | 2023-04 | 2029-01 | +2102 days |
| 2026-11-18 | Patritumab Deruxtecan | NCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | 2027-09-01 | 2030-11-19 | +1175 days |
| 2026-11-18 | Mitapivat | NCT05935202Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies | Phase 2 | 2025-07-15 | 2028-09-30 | +1173 days |
| 2026-11-18 | Obudanersen | NCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome | Phase 1/2 | 2029-03 | 2032-03 | +1096 days |
| 2026-11-18 | Tretinoin, Pembrolizumab | NCT06484920A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Phase 2 | 2027-12 | 2025-06-03 | −911 days |
| 2026-11-18 | Tobevibart (VIR-3434) | NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Phase 2 | 2026-11 | 2029-03 | +851 days |
| 2026-11-18 | Futibatinib (Lytgobi), Amivantamab, Atezolizumab | NCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | Phase 2 | 2025-05 | 2027-05 | +730 days |
| 2026-11-18 | Ivabradine | NCT04111133Ivabradine in Cirrhotic Cardiomyopathy | Phase na | 2024-10 | 2026-10-01 | +730 days |
| 2026-11-18 | Gemcitabine, S-1, Tislelizumab | NCT06903273Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma | Phase 2 | 2028-07-01 | 2030-07-01 | +730 days |
| 2026-11-18 | tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, Bictegravir | NCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity | Phase 3 | 2026-06-05 | 2027-12-05 | +548 days |
| 2026-11-18 | Letrozole | NCT06913075FET in Adenomyosis | Phase na | 2026-07-15 | 2027-09-15 | +427 days |
| 2026-11-18 | Ipilimumab, Nivolumab, tocilizumab | NCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | Phase 2 | 2027-12-31 | 2026-11-11 | −415 days |
| 2026-11-18 | INCB123667 | NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | 2028-11-15 | 2027-10-12 | −400 days |
| 2026-11-18 | Temozolomide | NCT04910022Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Phase 1/2 | 2027-05-30 | 2026-05-06 | −389 days |
| 2026-11-18 | Dexamethasone, Ixazomib | NCT03618537Ixazomib Maintenance Study in Patients With AL Amyloidosis | Phase 2 | 2026-08 | 2027-08 | +365 days |
| 2026-11-18 | Binimetinib | NCT06159478Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer | Phase 2 | 2027-02-28 | 2028-02-28 | +365 days |
| 2026-11-18 | Rifaximin (Xifaxan) | NCT06538077BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE | Phase 4 | 2026-08 | 2027-08 | +365 days |
| 2026-11-18 | Cannabidiol (Epidiolex) | NCT06014424Cannabidiol Medication Intervention Trial | Phase 2 | 2026-12-29 | 2027-12 | +337 days |
| 2026-11-18 | Gemcitabine, Atezolizumab | NCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Phase 3 | 2027-06-01 | 2026-07-23 | −313 days |
| 2026-11-18 | IAM1363 | NCT06253871A Phase 1/2 Study of IAM1363 in HER2 Cancers | Phase 1/2 | 2027-12 | 2028-10 | +305 days |
| 2026-11-18 | Diroximel fumarate | NCT06913920Mechanical Modalities Combined With Standard Therapy Versus Standard Therapy Alone for Edema and Pain Management After Distal Radius Fracture Fixation | Phase na | 2026-01-15 | 2026-10-28 | +286 days |
| 2026-11-18 | Pembrolizumab, Blinatumomab | NCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | Phase 1/2 | 2025-11-11 | 2025-01-31 | −284 days |
| 2026-11-18 | Methotrexate, etanercept | NCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS | Phase 3 | 2025-02-28 | 2025-10-31 | +245 days |
| 2026-11-18 | Entrectinib | NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Phase 2 | 2027-06-30 | 2026-10-29 | −244 days |
| 2026-11-18 | Diroximel fumarate | NCT06913894Supervised vs. Home-Based vs. No Therapy for Uncomplicated Distal Radius Fracture in Younger Adults | Phase na | 2026-04-21 | 2026-10-27 | +189 days |
| 2026-11-18 | faricimab | NCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Phase 3 | 2031-08 | 2032-02 | +184 days |
| 2026-11-18 | Insulin Lispro | NCT06945406A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | Phase 1 | 2027-03 | 2027-07 | +122 days |
| 2026-11-18 | viloxazine | NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | Phase 3 | 2026-09 | 2026-12 | +91 days |
| 2026-11-18 | Ranibizumab, Surabgene lomparvovec | NCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | 2026-08 | 2026-10-13 | +73 days |
| 2026-11-18 | Temozolomide | NCT06931626Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | Phase 1 | 2026-10-30 | 2026-08-20 | −71 days |
| 2026-11-18 | ARV-806 | NCT07023731A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | 2026-11-30 | 2026-10-30 | −31 days |
| 2026-11-18 | Depemokimab | NCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | Phase 3 | 2029-04-30 | 2029-04-02 | −28 days |
| 2026-11-18 | Temozolomide | NCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial | Phase 3 | 2035-11-02 | 2035-11-30 | +28 days |
| 2026-11-18 | Inclisiran | NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Phase 3 | 2027-02-11 | 2027-01-16 | −26 days |
| 2026-11-18 | Tafolecimab | NCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | 2026-09-06 | 2026-08-26 | −11 days |
| 2026-11-18 | Felcorekibart | NCT07915791A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | 2029-03-16 | 2029-03-07 | −9 days |
| 2026-11-18 | Rabeprazole | NCT07797478A Study of RO7890597 in Healthy Adult Volunteers | Phase 1 | 2027-06-08 | 2027-06-15 | +7 days |
| 2026-11-17 | Duloxetine, Pregabalin, Gabapentin | NCT07593313Treatment of Post-Stroke Central Pain | Phase na | 2026-08-01 | 2029-08-01 | +1096 days |
| 2026-11-17 | Avelumab | NCT03774901Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | Phase 2 | 2024-09-22 | 2026-10-30 | +768 days |
| 2026-11-17 | zanubrutinib, Rituximab | NCT05914662Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM | Phase 2 | 2025-03-15 | 2026-11-15 | +610 days |
| 2026-11-17 | zasocitinib | NCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase 3 | 2033-01-24 | 2034-07-03 | +525 days |
| 2026-11-17 | Bevacizumab, Nab-paclitaxel, Relacorilant (Lifyorli) | NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Phase 2 | 2026-08 | 2027-12 | +487 days |
| 2026-11-17 | Ramucirumab | NCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Phase 2 | 2027-09 | 2026-07-09 | −419 days |
| 2026-11-17 | TSN1611 | NCT06385925A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Phase 1/2 | 2026-10-30 | 2027-10-30 | +365 days |
| 2026-11-17 | Pembrolizumab | NCT03829254A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Phase 1/2 | 2026-08 | 2027-07 | +334 days |
| 2026-11-17 | Empagliflozin | NCT07472920Empagliflozin Adjunctive Therapy in Bipolar Depression | Phase na | 2026-09 | 2027-08 | +334 days |
| 2026-11-17 | dupilumab | NCT05268107Ethnic Differences in Mechanisms of Action of Dupilumab | Phase 4 | 2026-12 | 2027-07 | +212 days |
| 2026-11-17 | Rituximab | NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Phase 2 | 2026-10-01 | 2027-05-01 | +212 days |
| 2026-11-17 | Corteria COR-1167 | NCT06815471CRF2 Agonist for the Treatment of Worsening Heart Failure | Phase 2 | 2026-12 | 2027-07 | +212 days |
| 2026-11-17 | Nab-paclitaxel, Gemcitabine | NCT05064618Investigator-initiated Clinical Trial of MIKE-1 | Phase 1/2 | 2025-04-30 | 2025-10-02 | +155 days |
| 2026-11-17 | Axatilimab, Pembrolizumab | NCT07015853ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | Phase 2 | 2033-07 | 2033-12 | +153 days |
| 2026-11-17 | Durvalumab | NCT03768570Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Phase 2 | 2026-10-31 | 2027-03-31 | +151 days |
| 2026-11-17 | Iparomlimab and tuvonralimab | NCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | Phase 3 | 2032-08-31 | 2032-12-31 | +122 days |
| 2026-11-17 | Dostarlimab, Niraparib | NCT04068753Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer | Phase 2 | 2026-12 | 2026-08-06 | −117 days |
| 2026-11-17 | HRG2010 | NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations | Phase 3 | 2025-10-09 | 2026-01-29 | +112 days |
| 2026-11-17 | Pembrolizumab | NCT07732634Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer | Phase 2 | 2029-08 | 2029-11 | +92 days |
| 2026-11-17 | Dostarlimab | NCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer | Phase 3 | 2029-12-12 | 2030-03-13 | +91 days |
| 2026-11-17 | Daraxonrasib, Nab-paclitaxel, Gemcitabine | NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2028-06 | 2028-04 | −61 days |
| 2026-11-17 | GFH276 | NCT07198321A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | Phase 1/2 | 2027-09-22 | 2027-07-30 | −54 days |
| 2026-11-17 | Purinostat Mesylate | NCT07809217Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants | Phase 1 | 2026-10-31 | 2026-12-15 | +45 days |
| 2026-11-17 | VT-5006 | NCT07310264Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease | Phase 1 | 2026-09-28 | 2026-11-10 | +43 days |
| 2026-11-17 | Axatilimab | NCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | 2026-09 | 2026-08-27 | −5 days |
| 2026-11-14 | Ceralasertib, Durvalumab | NCT03780608A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L) | Phase 2 | 2022-12-01 | 2027-12-01 | +1826 days |
| 2026-11-14 | BI 3000202 | NCT06878365A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies | Phase 1 | 2026-12-06 | 2029-12-10 | +1100 days |
| 2026-11-14 | Oxycodone (Xtampza ER) | NCT04659317Opioid-Free Orthopaedics | Phase 3 | 2028-12 | 2026-07-20 | −865 days |
| 2026-11-14 | Elranatamab, Lenalidomide, Daratumumab | NCT06931704Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | Phase 2 | 2030-11-30 | 2028-11-30 | −730 days |
| 2026-11-14 | Rosuvastatin, Laroprovstat | NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | Phase 2/3 | 2025-07-03 | 2027-02-22 | +599 days |
| 2026-11-14 | Nabiximols | NCT05503147Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) | Phase 1 | 2023-08-01 | 2025-01-15 | +533 days |
| 2026-11-14 | OrcaGraft (Orca-Q) | NCT06900192A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis | Phase 1 | 2029-08 | 2028-06 | −426 days |
| 2026-11-14 | Osimertinib | NCT05748093Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat | Phase 4 | 2026-06-01 | 2027-07-01 | +395 days |
| 2026-11-14 | Omega-3-acid ethyl esters (Lovaza) | NCT02178410VITAL Rhythm Study | Phase 3 | 2026-10 | 2027-10 | +365 days |
| 2026-11-14 | pemetrexed, Adebrelimab, Nab-paclitaxel | NCT05794477A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | Phase 1/2 | 2025-07-01 | 2024-08-20 | −315 days |
| 2026-11-14 | obefazimod | NCT07453784Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | Phase 1 | 2026-09 | 2027-04 | +212 days |
| 2026-11-14 | aldesleukin | NCT06107894TIL Therapy for Patients With Advanced Solid Tumors | Phase 1 | 2025-09 | 2026-02-28 | +180 days |
| 2026-11-14 | metformin | NCT04931017Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer | Phase 2 | 2026-12-31 | 2026-07-09 | −175 days |
| 2026-11-14 | Vosoritide | NCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | 2027-03 | 2026-09-16 | −166 days |
| 2026-11-14 | upadacitinib | NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Phase 3 | 2028-03 | 2028-08 | +153 days |
| 2026-11-14 | Gemcitabine, Durvalumab | NCT07332351Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial | Phase 2 | 2027-01-01 | 2027-06-01 | +151 days |
| 2026-11-14 | Trastuzumab Emtansine, Inavolisib | NCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2026-12-31 | 2027-05-03 | +123 days |
| 2026-11-14 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2026-11-14 | 2026-08-13 | −93 days |
| 2026-11-14 | ADSTEM | NCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Phase 3 | 2029-06 | 2029-09 | +92 days |
| 2026-11-14 | Suzetrigine | NCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-14 | AZD4954 | NCT07812077A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954 | Phase 1 | 2026-12-17 | 2027-03-17 | +90 days |
| 2026-11-14 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-11-14 | 2026-08-25 | −81 days |
| 2026-11-14 | survodutide | NCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body | Phase 1 | 2027-01-26 | 2027-04-09 | +73 days |
| 2026-11-14 | maralixibat | NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | 2026-10 | 2026-07-29 | −64 days |
| 2026-11-14 | Omalizumab | NCT06618963Effect of Omalizumab in the Skin of Food Allergy Patients | Phase 4 | 2026-09 | 2026-11-03 | +63 days |
| 2026-11-14 | Bempedoic acid | NCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Phase 3 | 2025-10 | 2025-08-05 | −57 days |
| 2026-11-14 | Benralizumab | NCT04565483Predictive Signature of Benralizumab Response | Phase 4 | 2026-10 | 2026-08-19 | −43 days |
| 2026-11-14 | Esketamine | NCT05212571Long-term Pain Modulation by Intravenous Esketamine in CRPS | Phase na | 2026-10-01 | 2026-08-20 | −42 days |
| 2026-11-14 | setmelanotide | NCT06772597A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Phase 2 | 2026-10-31 | 2026-11-03 | +3 days |
| 2026-11-14 | Benralizumab | NCT03953300Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | Phase 4 | 2026-10-19 | 2026-10-20 | +1 day |
| 2026-11-13 | Nivolumab | NCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | Phase 2 | 2022-12-15 | 2030-12-15 | +2922 days |
| 2026-11-13 | Ibrutinib | NCT02787369ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | Phase 1 | 2026-04 | 2019-06 | −2496 days |
| 2026-11-13 | Axitinib | NCT06485908Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma | Phase 1/2 | 2026-04 | 2032-02 | +2132 days |
| 2026-11-13 | tenofovir alafenamide (Vemlidy) | NCT04939441Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) | Phase 4 | 2024-05-01 | 2027-12-31 | +1339 days |
| 2026-11-13 | Serplulimab | NCT05311189Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | Phase 2 | 2023-12-31 | 2026-12-31 | +1096 days |
| 2026-11-13 | Mavacamten | NCT07807384Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 4 | 2026-09 | 2029-09 | +1096 days |
| 2026-11-13 | LBL-034 | NCT06049290A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | Phase 1/2 | 2026-10-20 | 2029-09-20 | +1066 days |
| 2026-11-13 | Methylprednisolone | NCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial | Phase 3 | 2027-01-31 | 2029-01-31 | +731 days |
| 2026-11-13 | Atezolizumab | NCT05681039Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-13 | Sargramostim, Ipilimumab, Pembrolizumab | NCT04739618Metastatic Solid Cancer Clinical Trial | Phase 2 | 2024-12 | 2026-11-10 | +709 days |
| 2026-11-13 | IRX4204 | NCT06723171Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis | Phase 2 | 2026-03 | 2027-12 | +640 days |
| 2026-11-13 | Rituximab | NCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | Phase 2 | 2026-09-30 | 2028-05-31 | +609 days |
| 2026-11-13 | AK146D1 | NCT06929663A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors | Phase 1 | 2026-11-05 | 2028-06-30 | +603 days |
| 2026-11-13 | pemetrexed, Cadonilimab | NCT06762080Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | Phase 1/2 | 2026-10-30 | 2027-12-30 | +426 days |
| 2026-11-13 | infliximab | NCT06758024PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease | Phase na | 2026-01 | 2027-03 | +424 days |
| 2026-11-13 | Anakinra | NCT03587701Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease | Phase 2 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-11-13 | Epcoritamab | NCT06510361A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy | Phase 2 | 2026-05-01 | 2027-05-01 | +365 days |
| 2026-11-13 | Decitabine/cedazuridine (Inqovi) | NCT05178693Lutathera and ASTX727 in Neuroendocrine Tumours | Phase 1 | 2026-06-30 | 2027-05-30 | +334 days |
| 2026-11-13 | Cetuximab | NCT06447987Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Phase 1 | 2026-12-05 | 2027-10-29 | +328 days |
| 2026-11-13 | Ifebemtinib, Furmonertinib | NCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | Phase 1/2 | 2026-07-31 | 2025-09-20 | −314 days |
| 2026-11-13 | LAE102 | NCT06493084Evaluate LAE102 in Healthy and Overweight/Obese Subjects | Phase 1 | 2026-09-30 | 2027-06-30 | +273 days |
| 2026-11-13 | Sotorasib | NCT06659341A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Phase 1 | 2027-04-26 | 2027-11-30 | +218 days |
| 2026-11-13 | Tislelizumab | NCT06420440Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | Phase 2 | 2026-05-31 | 2026-12-31 | +214 days |
| 2026-11-13 | Naloxone (Narcan) | NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment | Phase 3 | 2026-08-31 | 2026-01-30 | −213 days |
| 2026-11-13 | Niraparib | NCT05694715Combination Therapy in Cancers With Mutations in DNA Repair Genes | Phase 1 | 2028-01-31 | 2028-08-31 | +213 days |
| 2026-11-13 | Lithium salicylate/L-proline (AL001) | NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder | Phase 1/2 | 2026-12 | 2027-07 | +212 days |
| 2026-11-13 | Rituximab | NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | Phase 1/2 | 2027-05-31 | 2026-11-06 | −206 days |
| 2026-11-13 | Pelcitoclax, Osimertinib | NCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | Phase 1 | 2025-12 | 2025-05-27 | −188 days |
| 2026-11-13 | Diroximel fumarate | NCT06913933Static vs. Dynamic Progressive Splinting for Persistent Wrist Stiffness After DRF | Phase na | 2026-04-17 | 2026-10-08 | +174 days |
| 2026-11-13 | Dexamethasone, Lenalidomide, Daratumumab, Carfilzomib | NCT03606577An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | Phase 2 | 2022-02-08 | 2022-07-18 | +160 days |
| 2026-11-13 | XTR003 | NCT07443696PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | Phase 2 | 2026-08 | 2026-12-31 | +152 days |
| 2026-11-13 | Emtricitabine (Emtriva), tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Dolutegravir, VH4524184 | NCT07202546A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | Phase 2 | 2027-06-11 | 2027-10-28 | +139 days |
| 2026-11-13 | Docetaxel, OSE2101 | NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | 2027-12-15 | 2028-05-01 | +138 days |
| 2026-11-13 | BI 3000202 | NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood | Phase 1 | 2026-10-06 | 2027-02-21 | +138 days |
| 2026-11-13 | Esketamine | NCT07753772Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction | Phase 4 | 2029-07 | 2029-11 | +123 days |
| 2026-11-13 | BI 3000202 | NCT07486102A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems | Phase 1 | 2027-02-26 | 2026-10-30 | −119 days |
| 2026-11-13 | Suzetrigine | NCT07538570Evaluation of Pain Treatment After Total Knee Arthroplasty | Phase 4 | 2027-01-30 | 2026-10-12 | −110 days |
| 2026-11-13 | Vosoritide | NCT06455059Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | Phase 3 | 2026-08-01 | 2026-04-23 | −100 days |
| 2026-11-13 | tocilizumab, Iberdomide, Obinutuzumab | NCT05169515A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2029-08-05 | 2029-04-30 | −97 days |
| 2026-11-13 | Bofanglutide | NCT07144098Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function | Phase 1 | 2026-07-12 | 2026-04-07 | −96 days |
| 2026-11-13 | Ifebemtinib | NCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | 2026-12-24 | 2027-03-24 | +90 days |
| 2026-11-13 | Saruparib | NCT06713369AZD5305 hADME in Patients With Advanced Solid Malignancies | Phase 1 | 2026-10-02 | 2026-12-31 | +90 days |
| 2026-11-13 | Erfonrilimab, Ifebemtinib, Nab-paclitaxel, Gemcitabine | NCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | Phase 1/2 | 2025-12-31 | 2025-10-11 | −81 days |
| 2026-11-13 | tulisokibart | NCT07133633A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | Phase 2 | 2027-06-15 | 2027-03-29 | −78 days |
| 2026-11-13 | Vadadustat | NCT06520826Vafseo Outcomes In-Center Experience | Phase 3 | 2026-06-30 | 2026-09-10 | +72 days |
| 2026-11-13 | Semaglutide (Wegovy), survodutide | NCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Phase 1 | 2027-01-08 | 2026-11-01 | −68 days |
| 2026-11-13 | Acoramidis | NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis | Phase 4 | 2027-07-15 | 2027-09-17 | +64 days |
| 2026-11-13 | Naloxone (Narcan) | NCT05027919Assessing a Clinically-meaningful Opioid Withdrawal Phenotype | Phase 2 | 2026-11-30 | 2027-01-30 | +61 days |
| 2026-11-13 | Esketamine | NCT07625826The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery | Phase na | 2027-05 | 2027-03 | −61 days |
| 2026-11-13 | Gabapentin | NCT06565546CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs | Phase na | 2026-09-01 | 2026-10-31 | +60 days |
| 2026-11-13 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2026-12-30 | 2027-02-26 | +58 days |
| 2026-11-13 | barzolvolimab | NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Phase 3 | 2026-10 | 2026-08-04 | −58 days |
| 2026-11-13 | tenofovir alafenamide (Vemlidy), Tenofovir disoproxil fumarate (Viread) | NCT02932150Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | 2026-09 | 2026-10-27 | +56 days |
| 2026-11-13 | barzolvolimab | NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Phase 3 | 2026-10 | 2026-08-12 | −50 days |
| 2026-11-13 | MET-233i | NCT07022977A Study of MET233 in Individuals With Obesity or Overweight | Phase 1 | 2026-04-21 | 2026-05-28 | +37 days |
| 2026-11-13 | Bofanglutide | NCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Phase 3 | 2026-05 | 2026-03-26 | −36 days |
| 2026-11-13 | MT-201 | NCT07219368A First-in-Human Single and Multiple Ascending Dose Study of MT-201 | Phase 1 | 2026-11-24 | 2026-10-20 | −35 days |
| 2026-11-13 | Ifebemtinib, Tislelizumab | NCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Phase 1/2 | 2025-12-24 | 2025-11-20 | −34 days |
| 2026-11-13 | tocilizumab, Pembrolizumab | NCT07889232Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | 2029-04-30 | 2029-05-31 | +31 days |
| 2026-11-13 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2029-01-01 | 2029-01-31 | +30 days |
| 2026-11-13 | Odronextamab, Rituximab | NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | 2028-02-07 | 2028-02-29 | +22 days |
| 2026-11-13 | GSK4527363 | NCT06576271A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants | Phase 1 | 2028-01-11 | 2028-02-01 | +21 days |
| 2026-11-13 | Ifebemtinib | NCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | Phase 1/2 | 2026-05-31 | 2026-05-11 | −20 days |
| 2026-11-13 | Ruxolitinib (Opzelura) | NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Phase 3 | 2026-10-09 | 2026-10-29 | +20 days |
| 2026-11-13 | Alimatravir | NCT07661108A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) | Phase 1 | 2026-10-09 | 2026-10-28 | +19 days |
| 2026-11-13 | precemtabart tocentecan | NCT06806046Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | Phase 1 | 2026-09-30 | 2026-09-23 | −7 days |
| 2026-11-13 | Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Carfilzomib | NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | 2026-08-30 | 2026-08-26 | −4 days |
| 2026-11-13 | setmelanotide | NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Phase 3 | 2025-12-22 | 2025-12-19 | −3 days |
| 2026-11-13 | Pegcetacoplan, BI 771716 | NCT06722157A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Phase 2 | 2026-10-28 | 2026-10-26 | −2 days |
| 2026-11-13 | Sevabertinib, metformin | NCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | Phase 1 | 2026-10-06 | 2026-10-08 | +2 days |
| 2026-11-11 | pemetrexed, Cemiplimab | NCT07720167Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer | Phase 2 | 2029-11-01 | 2035-08-01 | +2099 days |
| 2026-11-11 | Methotrexate | NCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | Phase 2/3 | 2026-07 | 2031-11 | +1949 days |
| 2026-11-11 | Luxdegalutamide | NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | 2032-03-15 | 2026-12-03 | −1929 days |
| 2026-11-11 | Vemurafenib, Pertuzumab, Dabrafenib, Pemigatinib, Entrectinib, Cobimetinib, Abemaciclib, Regorafenib, Tepotinib, Alectinib, Trametinib, Atezolizumab | NCT05159245The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | Phase 2 | 2026-11-25 | 2031-11-25 | +1826 days |
| 2026-11-11 | Bevacizumab | NCT07005570Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK) | Phase 2 | 2027-07-01 | 2031-12-31 | +1644 days |
| 2026-11-11 | aldesleukin | NCT04643574NeoTIL in Advanced Solid Tumors | Phase 1 | 2027-11 | 2023-10-24 | −1469 days |
| 2026-11-11 | Obinutuzumab, Gemcitabine | NCT06806033Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Phase 2 | 2027-01-31 | 2029-07-31 | +912 days |
| 2026-11-11 | Mepolizumab | NCT05923047Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. | Phase 4 | 2024-09-01 | 2027-01-01 | +852 days |
| 2026-11-11 | elasomeran | NCT04894435Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity | Phase 2 | 2024-11-15 | 2022-07-25 | −844 days |
| 2026-11-11 | Rituximab, Pirtobrutinib | NCT06263491Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-11 | Brigatinib | NCT03707938Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | Phase 1 | 2026-01-28 | 2028-01-28 | +730 days |
| 2026-11-11 | Pelacarsen | NCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | 2028-08-24 | 2026-10-15 | −679 days |
| 2026-11-11 | Rilvegostomig | NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | 2026-08-28 | 2028-06-01 | +643 days |
| 2026-11-11 | lutikizumab, risankizumab | NCT06865105Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | 2027-12 | 2029-08 | +609 days |
| 2026-11-11 | Sintilimab | NCT06054906Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer | Phase 2 | 2025-06-30 | 2026-12-30 | +548 days |
| 2026-11-11 | Colchicine (cardiovascular) | NCT06217120Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction | Phase 2 | 2025-10-01 | 2027-04 | +547 days |
| 2026-11-11 | Inclisiran | NCT06865885LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering | Phase 4 | 2026-12-30 | 2028-06-01 | +519 days |
| 2026-11-11 | Capecitabine, Gemcitabine | NCT06434493Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma | Phase na | 2028-06-01 | 2029-11-01 | +518 days |
| 2026-11-11 | Dexamethasone | NCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults | Phase na | 2027-08-31 | 2026-05-20 | −468 days |
| 2026-11-11 | Nab-paclitaxel, Gemcitabine | NCT03492671Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | Phase 2 | 2026-09 | 2027-10 | +395 days |
| 2026-11-11 | metformin | NCT07001878Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis | Phase 4 | 2026-08-31 | 2027-09-30 | +395 days |
| 2026-11-11 | Mepolizumab | NCT06041386REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study | Phase 4 | 2025-01-31 | 2026-02-12 | +377 days |
| 2026-11-11 | Trastuzumab Deruxtecan, Olaparib | NCT06525298EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Phase 1/2 | 2027-09 | 2028-09 | +366 days |
| 2026-11-11 | Cemiplimab | NCT05574101A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | Phase 2 | 2026-10-06 | 2027-10-06 | +365 days |
| 2026-11-11 | Fianlimab, Cemiplimab | NCT06848088A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | Phase 2 | 2029-10-10 | 2030-10-09 | +364 days |
| 2026-11-11 | Bofanglutide | NCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Phase 3 | 2027-09 | 2026-09-22 | −344 days |
| 2026-11-11 | Esketamine | NCT05450432Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | Phase 4 | 2026-06-01 | 2027-05-01 | +334 days |
| 2026-11-11 | Tislelizumab | NCT07557914Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes | Phase 2 | 2029-02 | 2029-12 | +303 days |
| 2026-11-11 | Vebreltinib | NCT07549061Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC | Phase 2 | 2028-05-30 | 2027-09-01 | −272 days |
| 2026-11-11 | Fianlimab, Cemiplimab, Pembrolizumab | NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Phase 3 | 2026-07-27 | 2027-01-15 | +172 days |
| 2026-11-11 | Bevacizumab | NCT06106308Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Phase 2 | 2026-11 | 2027-04-16 | +166 days |
| 2026-11-11 | Gemcitabine | NCT06454383Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | Phase 1 | 2026-11-13 | 2027-03-23 | +130 days |
| 2026-11-11 | Belumosudil | NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants | Phase 1 | 2026-09-28 | 2027-01-26 | +120 days |
| 2026-11-11 | Rosuvastatin, elecoglipron | NCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | Phase 1 | 2026-10-01 | 2027-01-25 | +116 days |
| 2026-11-11 | Ulonivirine | NCT07595263A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) | Phase 1 | 2027-01-15 | 2026-09-29 | −108 days |
| 2026-11-11 | Nab-paclitaxel, Bevacizumab | NCT05075993Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Phase 1 | 2027-02-02 | 2026-11-03 | −91 days |
| 2026-11-11 | HiCM-188 (allogeneic iPSC-cardiomyocytes) | NCT07646210HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery | Phase 1/2 | 2028-05 | 2028-02 | −90 days |
| 2026-11-11 | Bofanglutide, Semaglutide (Ozempic) | NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Phase 3 | 2026-12-11 | 2026-09-18 | −84 days |
| 2026-11-11 | Tirzepatide (Zepbound) | NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Phase 2/3 | 2027-01-01 | 2026-10-10 | −83 days |
| 2026-11-11 | Rosuvastatin, Bofanglutide | NCT07128888Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection | Phase 1 | 2026-07-05 | 2026-04-13 | −83 days |
| 2026-11-11 | Rifaximin (Xifaxan) | NCT05677282Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct | Phase 4 | 2025-09 | 2025-06-29 | −64 days |
| 2026-11-11 | Ranibizumab, Bevacizumab | NCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) | Phase 3 | 2026-07 | 2026-05-28 | −34 days |
| 2026-11-11 | tocilizumab | NCT07254637Tocilizumab in Chronic Inflammatory CPPD Disease | Phase 2 | 2026-10 | 2026-11 | +31 days |
| 2026-11-11 | retatrutide | NCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | 2027-07 | 2027-06 | −30 days |
| 2026-11-11 | linaclotide | NCT06692673Linaclotide for Colonoscopy Bowel Prep | Phase 1/2 | 2026-04-30 | 2026-04-07 | −23 days |
| 2026-11-11 | Aflibercept | NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Phase 3 | 2026-10 | 2026-09-09 | −22 days |
| 2026-11-11 | Cabotegravir/rilpivirine (Cabenuva) | NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed | Phase 3 | 2029-09-04 | 2029-08-13 | −22 days |
| 2026-11-11 | remibrutinib | NCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | Phase 1 | 2027-12-21 | 2027-11-29 | −22 days |
| 2026-11-11 | AMG 691 | NCT07745907A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers | Phase 1 | 2027-03-31 | 2027-03-17 | −14 days |
| 2026-11-11 | Bofanglutide | NCT07141030Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function | Phase 1 | 2025-10-09 | 2025-10-20 | +11 days |
| 2026-11-11 | Ibrutinib | NCT03479268Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | Phase 1 | 2026-11-05 | 2026-10-28 | −8 days |
| 2026-11-11 | Bofanglutide | NCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | Phase 3 | 2026-08-07 | 2026-07-30 | −8 days |
| 2026-11-11 | VCT220 | NCT07340320A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | 2027-04-16 | 2027-04-08 | −8 days |
| 2026-11-11 | metreleptin | NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL | Phase 3 | 2026-07-21 | 2026-07-14 | −7 days |
| 2026-11-11 | zenagamtide, Semaglutide (Ozempic) | NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | 2028-12-12 | 2028-12-19 | +7 days |
| 2026-11-11 | Naloxone (Narcan) | NCT07459166A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade | Phase 2 | 2026-07-22 | 2026-07-15 | −7 days |
| 2026-11-11 | Modafinil | NCT07830056Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived Personnel | Phase 4 | 2026-10 | 2026-09-24 | −7 days |
| 2026-11-11 | rilzabrutinib | NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Phase 3 | 2026-11-30 | 2026-11-25 | −5 days |
| 2026-11-11 | Bofanglutide | NCT07355738Bioequivalence Study of GZR18 Injection Before and After CMC Change | Phase 1 | 2026-05-20 | 2026-05-22 | +2 days |
| 2026-11-11 | lebrikizumab | NCT01987492A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma | Phase 2 | 2016-12-20 | 2016-12-19 | −1 day |
| 2026-11-10 | Pembrolizumab | NCT05394103Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | 2025-12-30 | 2029-03-31 | +1187 days |
| 2026-11-10 | IncobotulinumtoxinA (Xeomin) | NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Phase 3 | 2011-09 | 2013-11-12 | +803 days |
| 2026-11-10 | Nivolumab | NCT05964101Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | Phase 2 | 2025-08-01 | 2027-08-01 | +730 days |
| 2026-11-10 | Ocrevus Zunovo, Ocrelizumab | NCT07667322A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | Phase 1 | 2028-02-15 | 2026-09-01 | −532 days |
| 2026-11-10 | Ambroxol | NCT06193421High-Dose Ambroxol in GBA1-Related Parkinson | Phase 1/2 | 2025-02-27 | 2026-03-30 | +396 days |
| 2026-11-10 | Quemliclustat | NCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Phase 1/2 | 2026-12-01 | 2027-12-31 | +395 days |
| 2026-11-10 | Tremelimumab, Durvalumab | NCT05701488SIRT With Tremelimumab and Durvalumab for Resectable HCC | Phase 1 | 2026-10-01 | 2027-10-01 | +365 days |
| 2026-11-10 | Cladribine (MAVENCLAD®), natalizumab | NCT04178005Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | Phase 4 | 2026-08-30 | 2027-05-30 | +273 days |
| 2026-11-10 | Dexamethasone | NCT07607691Ultrasound-Guided PENG Block for Chronic Shoulder Pain | Phase na | 2026-10-01 | 2027-07-01 | +273 days |
| 2026-11-10 | Venetoclax, Ibrutinib, Lenalidomide, Obinutuzumab | NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Phase 1/2 | 2026-12-01 | 2027-08-12 | +254 days |
Showing the newest 300 of 2,453 moves. Each drug page lists every registry date for its own studies.
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.